Testosterone Measurement While Treating Prostate Cancer: Which Test and When?

[Nelson Vergel]

The Canadian consensus statement recommends achieving a serum testosterone level of less than 0.7nmol/l as there appears to be an associated clinical benefit9. Additional recommendations include regular monitoring of testosterone and PSA levels throughout the first year of ADT treatment, using validated LC-MS/MS methods for testosterone assays at low testosterone levels (<0.7 nmol/l) (0r 20 ng/dL)

In conclusion, lower testosterone levels correlate with better freedom from CRPC. Breakthrough testosterone levels above 1.7 nmol/l have higher rates of failure. Testosterone levels should be assessed periodically to ensure castrate levels (every 3- months), with confirmation of lab assays at low testosterone levels. Lastly, the role of testosterone and other serum androgens as prognostic and predictive biomarkers in mCRPC requires more study.
APCCC 2019: Testosterone Measurement - Which Test and When?

 

[wondering]

The Canadian consensus statement recommends achieving a serum testosterone level of less than 0.7nmol/l as there appears to be an associated clinical benefit9. Additional recommendations include regular monitoring of testosterone and PSA levels throughout the first year of ADT treatment, using validated LC-MS/MS methods for testosterone assays at low testosterone levels (<0.7 nmol/l) (0r 20 ng/dL)

In conclusion, lower testosterone levels correlate with better freedom from CRPC. Breakthrough testosterone levels above 1.7 nmol/l have higher rates of failure. Testosterone levels should be assessed periodically to ensure castrate levels (every 3- months), with confirmation of lab assays at low testosterone levels. Lastly, the role of testosterone and other serum androgens as prognostic and predictive biomarkers in mCRPC requires more study.
APCCC 2019: Testosterone Measurement - Which Test and When?

Then again, from my employer:

Is It Time for New Strategies to Treat Aggressive Prostate Cancer?